You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 19, 2024

RELPAX Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Relpax, and what generic alternatives are available?

Relpax is a drug marketed by Upjohn and is included in one NDA.

The generic ingredient in RELPAX is eletriptan hydrobromide. There are twelve drug master file entries for this compound. Eleven suppliers are listed for this compound. Additional details are available on the eletriptan hydrobromide profile page.

Summary for RELPAX
Drug patent expirations by year for RELPAX
Drug Prices for RELPAX

See drug prices for RELPAX

Drug Sales Revenue Trends for RELPAX

See drug sales revenues for RELPAX

Recent Clinical Trials for RELPAX

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.Phase 1
PfizerPhase 1
GlaxoSmithKlinePhase 3

See all RELPAX clinical trials

Anatomical Therapeutic Chemical (ATC) Classes for RELPAX
Paragraph IV (Patent) Challenges for RELPAX
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
RELPAX Tablets eletriptan hydrobromide 20 mg and 40 mg 021016 1 2010-03-29

US Patents and Regulatory Information for RELPAX

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Upjohn RELPAX eletriptan hydrobromide TABLET;ORAL 021016-001 Dec 26, 2002 AB RX Yes No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Upjohn RELPAX eletriptan hydrobromide TABLET;ORAL 021016-002 Dec 26, 2002 AB RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for RELPAX

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Upjohn RELPAX eletriptan hydrobromide TABLET;ORAL 021016-001 Dec 26, 2002 ⤷  Try a Trial ⤷  Try a Trial
Upjohn RELPAX eletriptan hydrobromide TABLET;ORAL 021016-002 Dec 26, 2002 ⤷  Try a Trial ⤷  Try a Trial
Upjohn RELPAX eletriptan hydrobromide TABLET;ORAL 021016-001 Dec 26, 2002 ⤷  Try a Trial ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Supplementary Protection Certificates for RELPAX

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0592438 SPC/GB01/023 United Kingdom ⤷  Try a Trial PRODUCT NAME: ELETRIPTAN AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, IN PARTICULAR THE HYDROBROMIDE SALT; REGISTERED: CH 55218 01 20001214; CH 52218 02 20001214; CH 52218 03 20001214; UK PL 00057/0452 20010212; UK PL 00057/0453 20010212; UK PL 00057/0454 20010212
0592438 C00592438/01 Switzerland ⤷  Try a Trial FORMER REPRESENTANTIVE: E. BLUM AND CO. PATENTANWAELTE, CH
0592438 36/2001 Austria ⤷  Try a Trial PRODUCT NAME: ELETRIPTAN UND DIE PHARMAZEUTISCH VERTRAEGLICHEN SALZE DAVON, EINSCHLIESSLICH DES HYDROBROMIDS; NAT. REGISTRATION NO/DATE: 1-24155 20010801; FIRST REGISTRATION: LI 55218 01, 55218 02 20001214
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.